This Medudy course is a conference report for physicians on the topic of "2026 ASCO GU – Symposium on Urogenital Cancer."
Prof. Dr. Axel S. Merseburger, Director of the Department of Urology at the Lübeck Campus
of the University Medical Center Schleswig-Holstein, will summarize the important study highlights of the congress for you.
The results of the dose escalation phase of the PAnTHA study evaluating 225Ac-PSMA-Trillium in advanced mCRPC will be presented, as well as the initial results of the Phase III KEYNOTE-B15 study investigating the efficacy and safety of perioperative enfortumab vedotin in muscle-invasive bladder cancer, and the results of an interim analysis from the Phase III LITESPARK-022 study comparing the combination of pembrolizumab and belzutifan with pembrolizumab monotherapy in clear cell renal cell carcinoma.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
By the end of this conference report, you will know:
- Some of the highlights of ASCO GU 2026
- The most important takeaways from the studies presented
- The expert's conclusion on the studies presented
